-$0.12 Earnings Per Share Expected for Aratana Therapeutics Inc (PETX) This Quarter

Brokerages expect that Aratana Therapeutics Inc (NASDAQ:PETX) will post earnings of ($0.12) per share for the current quarter, according to Zacks Investment Research. Three analysts have made estimates for Aratana Therapeutics’ earnings. The highest EPS estimate is ($0.10) and the lowest is ($0.14). Aratana Therapeutics posted earnings per share of ($0.19) during the same quarter last year, which would suggest a positive year over year growth rate of 36.8%. The business is expected to announce its next earnings results on Tuesday, March 12th.

According to Zacks, analysts expect that Aratana Therapeutics will report full year earnings of ($0.25) per share for the current fiscal year, with EPS estimates ranging from ($0.28) to ($0.23). For the next year, analysts forecast that the company will post earnings of ($0.22) per share, with EPS estimates ranging from ($0.32) to ($0.08). Zacks Investment Research’s EPS calculations are a mean average based on a survey of research firms that that provide coverage for Aratana Therapeutics.

Aratana Therapeutics (NASDAQ:PETX) last posted its quarterly earnings data on Thursday, November 1st. The biopharmaceutical company reported ($0.13) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.16) by $0.03. Aratana Therapeutics had a negative return on equity of 15.08% and a negative net margin of 52.94%. The company had revenue of $21.56 million for the quarter, compared to analysts’ expectations of $5.70 million.

PETX has been the topic of several research analyst reports. Zacks Investment Research upgraded Aratana Therapeutics from a “hold” rating to a “buy” rating and set a $5.75 price objective on the stock in a report on Tuesday, September 11th. BidaskClub cut Aratana Therapeutics from a “strong-buy” rating to a “buy” rating in a report on Tuesday, October 2nd. Stifel Nicolaus lowered their price objective on Aratana Therapeutics from $8.00 to $7.00 and set a “buy” rating on the stock in a report on Monday, August 6th. HC Wainwright set a $10.00 price objective on Aratana Therapeutics and gave the stock a “buy” rating in a report on Monday, November 5th. Finally, TheStreet upgraded Aratana Therapeutics from a “d” rating to a “c-” rating in a report on Wednesday, November 21st. Two equities research analysts have rated the stock with a hold rating, four have given a buy rating and one has assigned a strong buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus price target of $8.15.

PETX stock traded down $0.11 during trading on Tuesday, hitting $6.50. The stock had a trading volume of 410,886 shares, compared to its average volume of 368,256. The company has a current ratio of 3.17, a quick ratio of 2.70 and a debt-to-equity ratio of 0.02. Aratana Therapeutics has a twelve month low of $3.67 and a twelve month high of $7.16. The stock has a market cap of $316.06 million, a price-to-earnings ratio of -6.70 and a beta of 1.95.

In other news, insider Peter Steven St sold 11,513 shares of the business’s stock in a transaction that occurred on Tuesday, October 30th. The stock was sold at an average price of $5.86, for a total transaction of $67,466.18. Following the transaction, the insider now directly owns 562,720 shares in the company, valued at approximately $3,297,539.20. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, insider Ernst Heinen sold 19,308 shares of the business’s stock in a transaction that occurred on Wednesday, November 7th. The stock was sold at an average price of $6.95, for a total value of $134,190.60. Following the transaction, the insider now owns 135,694 shares in the company, valued at $943,073.30. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 106,513 shares of company stock worth $660,966. Insiders own 5.30% of the company’s stock.

Several institutional investors have recently modified their holdings of the company. BlackRock Inc. boosted its holdings in shares of Aratana Therapeutics by 2.7% during the 3rd quarter. BlackRock Inc. now owns 3,439,584 shares of the biopharmaceutical company’s stock worth $20,087,000 after purchasing an additional 91,344 shares during the last quarter. Engaged Capital LLC boosted its holdings in shares of Aratana Therapeutics by 20.0% during the 2nd quarter. Engaged Capital LLC now owns 2,400,000 shares of the biopharmaceutical company’s stock worth $10,200,000 after purchasing an additional 400,000 shares during the last quarter. Vanguard Group Inc. boosted its holdings in shares of Aratana Therapeutics by 3.8% during the 3rd quarter. Vanguard Group Inc. now owns 2,044,208 shares of the biopharmaceutical company’s stock worth $11,938,000 after purchasing an additional 75,166 shares during the last quarter. General American Investors Co. Inc. boosted its holdings in shares of Aratana Therapeutics by 15.9% during the 3rd quarter. General American Investors Co. Inc. now owns 1,874,364 shares of the biopharmaceutical company’s stock worth $10,946,000 after purchasing an additional 256,441 shares during the last quarter. Finally, Massachusetts Financial Services Co. MA boosted its holdings in shares of Aratana Therapeutics by 8.4% during the 3rd quarter. Massachusetts Financial Services Co. MA now owns 1,491,196 shares of the biopharmaceutical company’s stock worth $8,709,000 after purchasing an additional 114,998 shares during the last quarter. Institutional investors and hedge funds own 64.78% of the company’s stock.

About Aratana Therapeutics

Aratana Therapeutics, Inc, a pet therapeutics company, focuses on the licensing, development, and commercialization of therapeutics for dogs and cats in the United States and Belgium. Its product portfolio includes multiple therapeutics and therapeutic candidates in development consisting of small molecule pharmaceuticals and biologics.

Featured Story: Technical Analysis of Stocks and What It Means

Get a free copy of the Zacks research report on Aratana Therapeutics (PETX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Aratana Therapeutics (NASDAQ:PETX)

Receive News & Ratings for Aratana Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aratana Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit